Advances in Anal Cancer Prevention in People with HIV
Joel M. Palefsky, MD, FRCP (C)
Professor of Medicine, Division of Infectious Diseases
University of California, San Francisco, CA
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc. Copyright © 2024. All rights reserved.
Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine and Infectious Diseases at the University of California San Francisco School of Medicine. He trained in medicine and Internal Medicine at McGill University in Montreal Canada and in Infectious Diseases at Stanford University. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the founder and director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center. He is the vice-chair of the National Cancer Institute (NCI)-supported AIDS Malignancy Consortium. He is the chair of the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study, a national multi-site NIH study that showed that treatment of anal cancer precursor lesions prevents the development of anal cancer. He is founder and past president of the International Anal Neoplasia Society and is past president of the International Papillomavirus Society. He is founder and director of the International Papillomavirus Society International HPV Awareness campaign.
At the completion of this educational activity learners will:
1. Understand the current epidemiology of anal cancer in people living with HIV;
2. Be aware of the results of the ANCHOR study;
3. Be aware of HPV vaccination recommendations and new screening guidelines for anal cancer prevention in people living with HIV;
4. Understand gaps in knowledge in screening and treatment of anal high-grade squamous intraepithelial lesions.
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun (Course Director/Planner) has no relevant financial relationships to disclose.
- Dr. Keith M. Sigel (Moderator) has no relevant financial relationships to disclose.
- Dr. Joel M. Palefsky (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Consultant to Vir Biotechnologies, Roche Diagnostics, Abbott, Viron Therapeutics (w/ Viron stock options); Institutional Grants from Barinthus Biotherapeutics, Atila Biosystems, Spotlight Therapeutics, Merck. Dr. Palefsky supported his presentation and clinical recommendations with the best available evidence from the medical literature and submitted his slides in advance for adequate peer review. All relevant financial relationships have been mitigated.
This PRN CME activity is funded in part by unrestricted educational grants from Gilead Sciences and ViiV Healthcare.
Download Article PDF/Slides